Amebic liver abscess (ALA) is the most common complication of intestinal histolytic amoebic infection. A significant number of patients have no history of amebic dysentery. It is more common in young males. 85% of abscesses are solitary and 65-70% are located in the right lobe of the liver. Compared to bacterial liver abscesses, they are characterized by a slower onset, lower fever, and longer duration of disease. Anti-amoebic drug therapy can achieve 85% to 100% efficacy. The following points help to differentiate it from bacterial liver abscess: (a) History of amebic dysentery, which can be separated from the onset of liver abscess for a long time. (b) Amoebic trophozoites can be found in the patient’s fresh pus and blood stool test, whereas only amoebic encapsulation can be found in normal stool. (c) Anti-amoebic drug therapy (metronidazole) can achieve significant results in most patients. Treatment: Amoebic liver abscess is mainly treated with drugs. The preferred drug is methotrexate, which is effective in 85% to 100% of cases after 10 to 14 days of medication. Dehydrotestoquinine can also be used daily 1.0-1.5mg/kg intramuscularly for 5 days, followed by oral chloroquine phosphate 600mg/d, changing to 300mg/d two days later for 3 weeks. Surgical treatment is only used for huge superficial abscesses >10cm with risk of rupture, or for cases with secondary bacterial infection and ineffective drug treatment, which can be aspirated by puncture under ultrasound guidance or sealed drainage to avoid secondary bacterial infection.